Articles that tag ANRO but are mainly about other companies.
Completed enrollment in Phase 2 proof-of-concept trial for ALTO-101; topline data expected end of Q1 2026; FDA granted Fast Track Designation; addresses unmet need in cognitive impairment associated with schizophrenia affecting nearly all patients.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
